Clinical Trial Search

Primary: Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 — 81; 92; 68 Number of patients — p=0.202

Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters

Primary: Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 — 87; 95; 63 Number of patients — p=0.015

Primary: Annualized Height Velocity(cm/Year) After 26 Weeks — 10.68; 5.72 cm/year

Primary: Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine — 240; 222; 242; 217…

Primary: Number of Participants With Acute Radiation Toxicities Recorded According to Radiation Therapy Oncology Group (RTOG) — 22; 16 participants

Primary: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. — 6; 22 participants

Primary: The Primary Efficacy Endpoint for the Study is the Proportion of Treatment Failures Within 12 Months After Randomization to Study Drug. — 8; 8; 9; 11 participants…

Primary: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks — 71.6; 81.6; 4.5 Percentage of participants

Primary: Adverse Events — 0; 6 participants

Primary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min

Primary: pCR Rate — 56; 46; 32 percentage of participants — p=0.13

Primary: Infant Mortality Through 6 mo of Age — 764; 741 participants — p=0.36

Primary: Subjects With Testosterone in Normal Range After Treatment — 81.3 Percentage of Subjects

Primary: Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range — 78.8 Percentage of Subjects